Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (113799)	9/13/2000 6:19:03 PM
From: Jenna	Read Replies (1) \| Respond to of 120523

PIII..The delayed reaction Upgrade.. HPOW was upgraded twice on September 8, and it was called in the RTR room. Two upgrades are better than one.. It moved up well. MCDT, SATC, TSYS and then PIII were upgraded one by one. PIII was killed yesterday... and also upgraded to BUY. Today was PIII's moment of fame. IT was its turn to move up in the one day exaltation that usually results from an upgrade. Better late than never

To: Jenna who wrote (113799)	9/13/2000 6:41:28 PM
From: 2MAR$	Read Replies (1) \| Respond to of 120523

VRTX Raises $300 Million in Convertible Subordinated Debt Placement CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the sale of $300 million of Convertible Subordinated Notes, due September 2007, through a Rule 144A offering to qualified institutional buyers. The initial purchasers have an option to purchase an additional $45 million of Notes to cover over-allotments, if any. The offering is expected to close on September 19, 2000. These Notes are convertible into Vertex Common Stock at a price equal to $92.26 per share, subject to adjustment in certain circumstances, which represents a 22.0% premium over today's closing bid of $75.625. The Notes bear an interest rate of 5.0% per annum, have a 7-year term, and can be redeemed by Vertex subject to specified conditions. (Photo: newscom.com ) Vertex expects to use the net proceeds of the sale to fund clinical trials, preclinical studies and research and development, to invest in technologies that support its chemogenomics approach, to potentially acquire technologies, resources and products that could broaden its drug discovery platform and pipeline, and for working capital and general corporate purposes. Vertex has agreed to file a registration statement for the resale of the Notes and the shares of Common Stock issuable upon conversion of the Notes within 90 days after the closing of the offering. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities. This summary of the terms and conditions of the Notes is not intended to be a complete summary of the terms and conditions of such securities. The Notes and the Common Stock issuable upon conversion of the Notes have not been registered under the Securities Act of 1933 or any state securities laws, and are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act. Unless so registered, the Notes and Common Stock issued upon conversion of the Notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex has seven drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary, information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome. The foregoing information regarding Vertex's sale of Convertible Subordinated Notes is forward looking. While management makes its best efforts to be accurate in making forward-looking statements, any such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. Risk factors include uncertainties relating to the ability of the Company to use effectively the proceeds from the sale of the Notes. Investors are directed to consider other risks and uncertainties discussed in Vertex documents filed with the Securities and Exchange Commission. Vertex's press releases are available at www.vpharm.com, or by fax-on- demand at (800) 758-5804 - Code: 938395.

To: Jenna who wrote (113799)	9/15/2000 8:25:39 AM
From: 2MAR$	Respond to of 120523

Alpha Industries-AHAA initiate with a strong buy @ PRUS Recommendations Celeritek-CLTK initiate with a strong buy @ PRUS Amgen-AMGN defending the stock@SBSH-dilutive acq not really likely 67<-4 5/8 EXFO Electro-Optical-EXFO upgraded from a hold to buy@CIBC Recommendations Oracle-ORCL raised price target from 109 to 114 @CIBC Recommendations VRTY) 42 1/2: Posts Q1 earnings of $0.20 a share, 6 cents above Wall Street views, vs year-ago earnings of $0.10. Revenues increased 58% to $31.3 mln. FIBR) 40: Posts a Q2 loss from continuing ops of $1.21 a share, vs yr-ago loss of $0.29. Revenues declined 33.9% to $11.376 mln. Sorrento Networks reported revenues of $3.5 mln, up 133% from the yr ago, but off 25% sequentially. 07:35 ET The Gap (GPS) 25 1/4: Current valuation and EPS growth prospects suggests that downside risk in stock is minimal (following 45% ytd decline), according to Business Week, citing money manager David Post. Noting company's history of bouncing back from problems, Post sees stock doubling in 18 months. 07:29 ET QUALCOMM (QCOM) 62 5/8: Stock may be ready for a rebound, says Business Week. According to money manger Graham Tanaka, some of the major negatives that hurt stock have turned positive -- such as China deciding to use CDMA again. Says QCOM destined to become the Intel of the wireless space. Tanaka sees stock climbing to $150 in three yrs.... QCOM shares bid at $62 7/8 in pre-market. 07:25 ET Xerox Corp (XRX) 16: Business DJN: DJ Qwest Commun Boosts DSL Speed To 640Kbps From 256Kbps 25 1/4: ABN AMRO downgrades to OUTPERFORM from BUY on heels of Q2 earnings report. RHAT posted a loss of of $0.01 a share, vs mean loss estimate of $0.02. Revenues rose 76% to $18.5 mln..... Stock trading at $24 in pre-market.